Clinical Data From Phase I Dose-Escalation Study Of NKTR-214

Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.02/22/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news